Inovio disclosed March 12, 2026 that it eliminated roles that do not directly support advancing INO-3107 toward U.S. approval, reducing its workforce from 134 employees in February 2025 to 112 as of March 11, 20264
INO-3107 is a DNA-based medicine designed to turn T cells against cells infected with human papillomavirus strains that cause recurrent respiratory papillomatosis, a rare condition affecting the vocal cords4
The FDA has warned that it might not consider Inovio's rare disease candidate for accelerated approval, and the agency has agreed to meet with Inovio about the issue, though the meeting has not yet been scheduled4
This represents Inovio's latest workforce reduction as the company continues to focus resources on its lead rare disease program while facing regulatory challenges4
Sources:
4. https://www.fiercebiotech.com/biotech/inovio-trims-team-trouble-brews-fda-rare-disease-candidate